GlaxoSmithKline (GSK) and the Singapore Economic Development Board (EDB) jointly awarded funding for eight research projects based in Singapore aimed at growing local capabilities and talent in green and sustainable manufacturing.

The first round of projects will receive close to US$3.5 million in funding under the US$24 million GSK-Singapore Partnership for Green & Sustainable Manufacturing. The partnership will be funded by GSK-EDB US$35 million joint fund to grow Singapore’s capabilities and talent base in green and sustainable manufacturing as well as healthcare policy. The joint fund is part of GSK-Singapore 10- year Strategic Roadmap to address the industry’s challenges and co-create innovative solutions.

“GSK is committed to the sustainability of our company, our people, our facilities, and the communities in which we operate. The funds we are committing for the research on green and sustainable manufacturing over 10 years will help Singapore to become a leader in sustainability research in pharmaceuticals and fine chemicals manufacturing and ensure that companies, such as GSK, can improve the efficiency of all activities by minimising materials, energy and waste worldwide,” said Mr Andrew Witty, Chief Executive Officer, GlaxoSmithKline.

The inaugural awards were presented today to the eight principal investigators from the Institute of Chemical and Engineering Sciences (ICES), Nanyang Technological University (NTU) and the National University of Singapore (NUS). They will work on research projects in chemical-, physical-and bio-transformations to maximise resource efficiency and minimise waste generated during the manufacturing process. The eight lead investigators are expected to recruit 17 post-doctoral and PhD researchers.

To find out more about how Singapore pioneers manufacturing excellence in pharmaceuticals manufacturing, please click here.